The negative association between C-reactive protein-albumin-lymphocyte index and cardiovascular disease

Shuaiqing Chen1, Mingshen Lin2, Jing Ye1

  • 1Department of Cardiology, Lishui Hospital of Traditional Chinese Medicine, China.

Insights

The C-reactive protein-albumin-lymphocyte (CALLY) index shows a significant inverse association with cardiovascular disease prevalence and mortality. Higher CALLY index scores are linked to reduced cardiovascular disease risk and better prognosis in adults.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Research
  • Public Health

Background:

  • The prognostic role of the C-reactive protein-albumin-lymphocyte (CALLY) index for cardiovascular disease (CVD) in the general population requires further investigation.
  • Existing research on the CALLY index's predictive capabilities for CVD outcomes is limited.

Purpose of the Study:

  • To evaluate the association between the CALLY index and the prevalence and mortality of cardiovascular disease.
  • To assess the CALLY index's utility in predicting cardiovascular disease outcomes in a large adult cohort.

Main Methods:

  • Analysis of data from 22,848 adults spanning 1999-2010.
  • Multivariate logistic regression and Cox proportional hazards models were used to examine associations.
  • Restricted cubic splines, Kaplan-Meier curves, and time-dependent ROC curves were employed for comprehensive analysis.

Main Results:

  • A 1-unit increase in ln CALLY index correlated with an 11% reduction in CVD prevalence (OR=0.89) and a 15% decrease in CVD mortality risk (HR=0.85).
  • The highest CALLY index quartile showed a 33% lower CVD prevalence and 39% reduced CVD mortality risk compared to the lowest quartile.
  • The ln CALLY index demonstrated strong predictive ability for 1-year CVD mortality (AUC=0.819).

Conclusions:

  • The CALLY index is significantly inversely associated with cardiovascular disease prevalence and mortality.
  • The CALLY index demonstrates reliable discriminatory capacity for predicting early cardiovascular disease mortality.
  • The CALLY index serves as a valuable prognostic biomarker for cardiovascular disease outcomes.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
619
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
591
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460